Cargando…
N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
BACKGROUND AND AIMS: Accumulating evidence suggests that the primary and acquired resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple molecular, cellular, and microenvironmental mechanisms. Understanding these mechanisms will enhance the likelihood of effective sorafeni...
Autores principales: | Xu, Junjie, Wan, Zhe, Tang, Minyue, Lin, Zhongjie, Jiang, Shi, Ji, Lin, Gorshkov, Kirill, Mao, Qijiang, Xia, Shunjie, Cen, Dong, Zheng, Junhao, Liang, Xiao, Cai, Xiujun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681956/ https://www.ncbi.nlm.nih.gov/pubmed/33222692 http://dx.doi.org/10.1186/s12943-020-01281-8 |
Ejemplares similares
-
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
por: Xu, Junjie, et al.
Publicado: (2020) -
miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
por: Ji, Lin, et al.
Publicado: (2020) -
UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma
por: Xu, Junjie, et al.
Publicado: (2021) -
N(6)
‐methyladenosine‐modified circRNA RERE modulates osteoarthritis by regulating β‐catenin ubiquitination and degradation
por: Liu, Yuxi, et al.
Publicado: (2022) -
TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
por: Xia, Shunjie, et al.
Publicado: (2021)